DNMT3A and breast cancer: VPA/hydralazine significantly downregulated protein expression of DNMT3a in the mammary tumors of HF offspring (p = 0.03 Holm-Sidak test after 2-way ANOVA, p for treatment = 0.046) (Fig. 6a, Supplementary Fig. 7).